icon-folder.gif   Conference Reports for NATAP  
61th Annual Meeting of the American Association for the Study of Liver Diseases
Boston, MA, Hynes Convention Center
October 30-November 3, 2010
Back grey_arrow_rt.gif
A Phase IIa Study of IDX184 in Combination with Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Treatment-Naïve Genotype 1 HCV-Infected Subjects
  Reported by Jules Levin
AASLD October 29-November 2, 2010 Boston, Massachusetts
J. Lalezari1, W. O'Riordan2, F. Poordad3, T. Nguyen4, G. Dubuc Patrick5, J. Chen5, X.J. Zhou5, J. Z. Sullivan-Bólyai5, D. Mayers5 and the IDX-08C-004 Investigator Group
1Quest Clinical Research, San Francisco, CA; 2e Study Site, San Diego, CA; 3Cedars-Sinai Medical Center, Los Angeles, CA; 4San Diego, CA; 5Idenix Pharmaceuticals, Inc., Cambridge, MA